we believe we have developed proprietary state-of-the-art manufacturing and scale-up techniques that allow synthesis and purification of our product candidates to support clinical development as well as potential commercialization . we have entered into certain manufacturing and supply arrangements with third-party suppliers which will in part utilize these techniques to support production of certain of our product candidates -50- and their components . we currently do not have any of our own internal mid-to-large scale manufacturing capabilities to support our product candidates . the basis of our novel rna-targeted therapeutics is the pmo . our next generation pmo-based chemistries include pmo-x ® , pmo plus ® and ppmo . pmos are highly resistant to degradation by enzymes , potentially enabling robust and sustained biological activity . in contrast to other rna-targeted therapeutics , which are usually designed to down-regulate protein expression , our technologies are designed to selectively up-regulate or down-regulate protein expression , and more importantly , create novel proteins . pmos have demonstrated inhibition of messenger rna ( mrna ) translation and alteration of pre-mrna splicing . the chemistry of pmo-based molecules has the potential to reduce off-target effects , such as the immune stimulation often observed with ribose-based rna technologies . we believe that our highly differentiated , novel , proprietary and innovative rna-targeted pmo-based platforms may represent a significant improvement over other rna-targeted technologies . in addition , pmos are highly adaptable molecules : with minor structural modifications , they can potentially be rapidly designed to target specific tissues , genetic sequences , or pathogens , and therefore , we believe they could potentially be applied to treat a broad spectrum of diseases . we have not generated any revenue from product sales to date and there can be no assurance that revenue from product sales will be achieved . even if we do achieve revenue from product sales , we are likely to continue to incur operating losses in the near term . as of december 31 , 2014 , we had approximately $ 211.1 million of cash , cash equivalents and investments , consisting of $ 73.6 million of cash and cash equivalents , $ 136.8 million of short-term investments and $ 0.8 million of restricted cash and investments . we believe that our balance of cash , cash equivalents and investments is sufficient to fund our current operational plan for the next twelve months . as of december 31 , 2014 , we have completed all development activities under the agreements with the dod . we are currently exploring possibilities for funding , collaboration and other avenues to support further development of these ebola , marburg and influenza product candidates . without funding from the u.s. government , we would likely curtail certain infectious disease research and development efforts , though we may pursue additional cash resources through public or private financings , seek additional government contracts and establish collaborations with or license our technology to other companies . the likelihood of our long-term success must be considered in light of the expenses , difficulties and delays frequently encountered in the development and commercialization of new pharmaceutical products , competitive factors in the marketplace , the risks associated with government sponsored programs and the complex regulatory environment in which we operate . there can be no assurance that we will ever achieve significant revenue or profitable operations . summary and timeline of eteplirsen data disclosure in october 2010 , we announced results from a clinical trial of eteplirsen ( avi study 28 ) . data from this study were published in the lancet in july 2011. avi study 28 was a phase ib/iia open label , dose-ranging , clinical trial assessing the safety , tolerability , pharmacokinetics and exploratory efficacy of eteplirsen in ambulatory individuals with dmd . participants in avi study 28 were between the ages of five and 15 with errors in the gene coding for dystrophin , which were amenable to treatment by skipping exon 51. participants were dosed once per week for 12 weeks . a total of 19 participants were enrolled and these individuals were assigned to one of six dose cohorts of 0.5 , 1.0 , 2.0 , 4.0 , 10.0 or 20.0 mg/kg . of the 19 participants enrolled , 18 received at least ten of the 12 doses planned in this trial . after completion of dosing , participants were followed for an additional 14 weeks . muscle biopsies were taken before treatment and 17 participants had a second biopsy at week 14 , two weeks after administration of the final dose . the primary objective of the trial was to assess the safety of eteplirsen at these doses over the 26-week duration of the trial . secondary trial objectives included assessment of plasma pharmacokinetics , urinary elimination and exploratory endpoints evaluating biological activity and clinical performance . this trial was conducted by investigators in the united kingdom at -51- the university college london institute of child health / great ormond street hospital in london and at the royal victoria infirmary in newcastle-upon-tyne . in avi study 28 , ( i ) eteplirsen induced exon 51 skipping in all cohorts and new dystrophin protein expression in cohort 3 ; ( ii ) eteplirsen was well tolerated in all participants with no drug-related serious adverse events or severe adverse events observed , except that one participant exhibited deteriorating cardiac function , which was considered probably disease related ; ( iii ) adverse events were mostly mild or moderate in intensity , not dose-related , and none were considered probably or definitely related to eteplirsen ; and ( iv ) there was no detectable immune response to newly made dystrophin . story_separator_special_tag in addition , there was a mean increase in forced vital capacity ( fvc ) , a measure of lung volume , of 11.0 percent . fvc percent predicted ( fvc adjusted for age and height ) was maintained above a mean of 90 percent at week 144 , with 101.3 percent at baseline and 90.9 percent at week 144. through 144 weeks , eteplirsen was well tolerated and there were no reported clinically significant treatment-related adverse events and no treatment-related serious adverse events . in addition , there were no treatment-related hospitalizations or discontinuations . in january 2015 , we announced that at week 168 , the six patients in the mitt population in the 30 and 50 mg/kg eteplirsen cohorts who were able to perform the 6mwt experienced a decline of 76.7 meters , or about 19.5 percent , from baseline in walking ability . a statistically significant treatment benefit of 65.4 meters ( p < 0.017 ) was observed compared with the placebo/delayed-treatment cohort ( n=4 ) , which initiated treatment at week 25 following 24 weeks of placebo . this cohort , after experiencing a substantial decline of 68.4 meters from baseline to week 36 , demonstrated a decline of 73 meters in walking ability from week 36 through week 168 , the period from which meaningful levels of dystrophin were likely produced . these analyses were based on the maximum 6mwt score when the test was performed on two consecutive days . respiratory muscle function from baseline through week 168 in the intent-to-treat population ( n=12 ) , as measured by maximum inspiratory and expiratory pressure ( mip and mep ) , continued to show a 11.1 percent mean increase in mip and a 14.7 percent mean increase in mep . analyses of mip percent predicted ( mip adjusted for weight ) and mep percent predicted ( mep adjusted for age ) demonstrated a mean change from 91.7 percent at baseline to 89.5 percent at week 168 in mip percent predicted , and a mean change from 79.3 percent at baseline to 74.3 percent at week 168 in mep percent predicted . in addition , there was a mean increase in fvc , a measure of lung volume , of 11.6 percent . fvc percent predicted ( fvc adjusted for age and height ) was maintained above a mean of 90 percent at week 168 , with 101.3 percent at baseline and 91.9 percent at week 168. through 168 weeks , -55- eteplirsen was well tolerated and there were no reported clinically significant treatment-related adverse events and no treatment-related serious adverse events . in addition , there were no treatment-related hospitalizations or discontinuations . summary and timeline of marburg product candidate data disclosures non-human primates infected with marburg virus and treated with our precursor product candidate , avi-6003 , achieved 100 % survival and primates infected with ebola virus and treated with avi-6002 achieved 80 % survival , in each case compared to universal lethality in both control groups . in addition to survival , primates treated with avi-6002 and avi-6003 have demonstrated decreases in levels of viremia , in harmful inflammatory indicators and in virus induced liver damage . additional data have also demonstrated that the surviving animals were resistant to viral infection after subsequent injection with the virus . during the 2012 fiscal year , we completed phase i single ascending-dose studies in healthy adult volunteers with its drug candidates for the treatment of ebola virus and marburg virus demonstrating positive safety data for each therapeutic candidate . in february 2012 , we announced positive safety results from all six cohorts of our phase i single ascending dose trials of avi-6002 and avi-6003 . for each group , safety , clinical laboratory and renal biomarker results through five days after treatment were reviewed by an independent data and safety monitoring board ( dsmb ) , which issued recommendations for both studies to progress as planned to multiple ascending dose studies after no safety concerns were identified . the phase i single ascending dose trials were designed to characterize the safety , tolerability and pharmacokinetics of each therapeutic candidate in healthy adult volunteers . in the two studies , a total of 60 healthy human subjects ( five per group ) were enrolled into six sequential dose groups ( 0.01 , 0.1 , 1.0 , 3.0 , 6.0 or 9.0 mg/kg ) . within each group , four subjects received the indicated dose of the therapeutic and one subject received placebo . final , unblinded safety and pharmacokinetic results for all subjects were completed in 2012. in july 2012 , we announced that avi-7288 , one of the two components that make up avi-6003 , demonstrated up to 100 % survival in a non-human primate study exploring the drug 's effect when the initiation of treatment is delayed to various time points post-infection . this study showed a high degree of survival between 83 % and 100 % in each of four post-exposure cohorts that received daily treatments with avi-7288 beginning 1- , 24- , 48- , or 96-hours after infection , compared to 0 % survival in the placebo-treated control group . in march 2013 , we announced positive results from a non-human primate study of avi-7288 . the data showed that intramuscular administration of avi-7288 resulted in survival rates up to 100 percent in treated subjects , similar to efficacy observed in previous studies that evaluated the drug when administered by intravenous injection . we initiated a phase i multiple ascending dose study in may 2013 , designed to characterize the safety , tolerability and pharmacokinetics of multiple doses of avi-7288 in healthy adult volunteers . the randomized , double-blind and placebo-controlled study has been overseen by an independent dsmb , which reviewed the safety and clinical laboratory data after each dose cohort prior to enrolling the next higher dose cohort . the final cohort completed dosing in the first quarter of

cash flows the following table summarizes our cash flow activity for each of the periods indicated : replace_table_token_9_th operating activities . the increase in the amount of cash used in operating activities of $ 63.8 million for 2014 compared to 2013 was primarily due to an increase in operating loss of $ 43.5 million driven by lower government contract revenue and higher research and development and general and administrative expenses due to corporate growth and $ 34.4 million from unfavorable changes in operating assets and liabilities primarily driven by advanced payments related to our future inventory commitments . this was partially offset by an increase of $ 13.6 million in non-cash adjustments to net loss . the increase in the amount of cash used in operating activities of $ 35.0 million for 2013 compared to 2012 was primarily due to an increase in operating loss of $ 60.6 million driven by lower government contract revenue and higher research and development costs and higher general and administrative costs , partially offset by an increase of $ 8.0 million in non-cash adjustments to net loss in 2013 as compared to 2012 as well as $ 17.6 million from favorable changes in operating assets and liabilities . investing activities . the increase in the amount of cash used in investing activities of $ 147.4 million for 2014 compared to 2013 was primarily due to the purchase of available-for-sale securities of $ 274.4 million and an increase of $ 23.1 million in capital expenditures partially due to the acquisition of the andover facility .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```cash flows the following table summarizes our cash flow activity for each of the periods indicated : replace_table_token_9_th operating activities . the increase in the amount of cash used in operating activities of $ 63.8 million for 2014 compared to 2013 was primarily due to an increase in operating loss of $ 43.5 million driven by lower government contract revenue and higher research and development and general and administrative expenses due to corporate growth and $ 34.4 million from unfavorable changes in operating assets and liabilities primarily driven by advanced payments related to our future inventory commitments . this was partially offset by an increase of $ 13.6 million in non-cash adjustments to net loss . the increase in the amount of cash used in operating activities of $ 35.0 million for 2013 compared to 2012 was primarily due to an increase in operating loss of $ 60.6 million driven by lower government contract revenue and higher research and development costs and higher general and administrative costs , partially offset by an increase of $ 8.0 million in non-cash adjustments to net loss in 2013 as compared to 2012 as well as $ 17.6 million from favorable changes in operating assets and liabilities . investing activities . the increase in the amount of cash used in investing activities of $ 147.4 million for 2014 compared to 2013 was primarily due to the purchase of available-for-sale securities of $ 274.4 million and an increase of $ 23.1 million in capital expenditures partially due to the acquisition of the andover facility .
```    
 Suspicious Activity Report : we believe we have developed proprietary state-of-the-art manufacturing and scale-up techniques that allow synthesis and purification of our product candidates to support clinical development as well as potential commercialization . we have entered into certain manufacturing and supply arrangements with third-party suppliers which will in part utilize these techniques to support production of certain of our product candidates -50- and their components . we currently do not have any of our own internal mid-to-large scale manufacturing capabilities to support our product candidates . the basis of our novel rna-targeted therapeutics is the pmo . our next generation pmo-based chemistries include pmo-x ® , pmo plus ® and ppmo . pmos are highly resistant to degradation by enzymes , potentially enabling robust and sustained biological activity . in contrast to other rna-targeted therapeutics , which are usually designed to down-regulate protein expression , our technologies are designed to selectively up-regulate or down-regulate protein expression , and more importantly , create novel proteins . pmos have demonstrated inhibition of messenger rna ( mrna ) translation and alteration of pre-mrna splicing . the chemistry of pmo-based molecules has the potential to reduce off-target effects , such as the immune stimulation often observed with ribose-based rna technologies . we believe that our highly differentiated , novel , proprietary and innovative rna-targeted pmo-based platforms may represent a significant improvement over other rna-targeted technologies . in addition , pmos are highly adaptable molecules : with minor structural modifications , they can potentially be rapidly designed to target specific tissues , genetic sequences , or pathogens , and therefore , we believe they could potentially be applied to treat a broad spectrum of diseases . we have not generated any revenue from product sales to date and there can be no assurance that revenue from product sales will be achieved . even if we do achieve revenue from product sales , we are likely to continue to incur operating losses in the near term . as of december 31 , 2014 , we had approximately $ 211.1 million of cash , cash equivalents and investments , consisting of $ 73.6 million of cash and cash equivalents , $ 136.8 million of short-term investments and $ 0.8 million of restricted cash and investments . we believe that our balance of cash , cash equivalents and investments is sufficient to fund our current operational plan for the next twelve months . as of december 31 , 2014 , we have completed all development activities under the agreements with the dod . we are currently exploring possibilities for funding , collaboration and other avenues to support further development of these ebola , marburg and influenza product candidates . without funding from the u.s. government , we would likely curtail certain infectious disease research and development efforts , though we may pursue additional cash resources through public or private financings , seek additional government contracts and establish collaborations with or license our technology to other companies . the likelihood of our long-term success must be considered in light of the expenses , difficulties and delays frequently encountered in the development and commercialization of new pharmaceutical products , competitive factors in the marketplace , the risks associated with government sponsored programs and the complex regulatory environment in which we operate . there can be no assurance that we will ever achieve significant revenue or profitable operations . summary and timeline of eteplirsen data disclosure in october 2010 , we announced results from a clinical trial of eteplirsen ( avi study 28 ) . data from this study were published in the lancet in july 2011. avi study 28 was a phase ib/iia open label , dose-ranging , clinical trial assessing the safety , tolerability , pharmacokinetics and exploratory efficacy of eteplirsen in ambulatory individuals with dmd . participants in avi study 28 were between the ages of five and 15 with errors in the gene coding for dystrophin , which were amenable to treatment by skipping exon 51. participants were dosed once per week for 12 weeks . a total of 19 participants were enrolled and these individuals were assigned to one of six dose cohorts of 0.5 , 1.0 , 2.0 , 4.0 , 10.0 or 20.0 mg/kg . of the 19 participants enrolled , 18 received at least ten of the 12 doses planned in this trial . after completion of dosing , participants were followed for an additional 14 weeks . muscle biopsies were taken before treatment and 17 participants had a second biopsy at week 14 , two weeks after administration of the final dose . the primary objective of the trial was to assess the safety of eteplirsen at these doses over the 26-week duration of the trial . secondary trial objectives included assessment of plasma pharmacokinetics , urinary elimination and exploratory endpoints evaluating biological activity and clinical performance . this trial was conducted by investigators in the united kingdom at -51- the university college london institute of child health / great ormond street hospital in london and at the royal victoria infirmary in newcastle-upon-tyne . in avi study 28 , ( i ) eteplirsen induced exon 51 skipping in all cohorts and new dystrophin protein expression in cohort 3 ; ( ii ) eteplirsen was well tolerated in all participants with no drug-related serious adverse events or severe adverse events observed , except that one participant exhibited deteriorating cardiac function , which was considered probably disease related ; ( iii ) adverse events were mostly mild or moderate in intensity , not dose-related , and none were considered probably or definitely related to eteplirsen ; and ( iv ) there was no detectable immune response to newly made dystrophin . story_separator_special_tag in addition , there was a mean increase in forced vital capacity ( fvc ) , a measure of lung volume , of 11.0 percent . fvc percent predicted ( fvc adjusted for age and height ) was maintained above a mean of 90 percent at week 144 , with 101.3 percent at baseline and 90.9 percent at week 144. through 144 weeks , eteplirsen was well tolerated and there were no reported clinically significant treatment-related adverse events and no treatment-related serious adverse events . in addition , there were no treatment-related hospitalizations or discontinuations . in january 2015 , we announced that at week 168 , the six patients in the mitt population in the 30 and 50 mg/kg eteplirsen cohorts who were able to perform the 6mwt experienced a decline of 76.7 meters , or about 19.5 percent , from baseline in walking ability . a statistically significant treatment benefit of 65.4 meters ( p < 0.017 ) was observed compared with the placebo/delayed-treatment cohort ( n=4 ) , which initiated treatment at week 25 following 24 weeks of placebo . this cohort , after experiencing a substantial decline of 68.4 meters from baseline to week 36 , demonstrated a decline of 73 meters in walking ability from week 36 through week 168 , the period from which meaningful levels of dystrophin were likely produced . these analyses were based on the maximum 6mwt score when the test was performed on two consecutive days . respiratory muscle function from baseline through week 168 in the intent-to-treat population ( n=12 ) , as measured by maximum inspiratory and expiratory pressure ( mip and mep ) , continued to show a 11.1 percent mean increase in mip and a 14.7 percent mean increase in mep . analyses of mip percent predicted ( mip adjusted for weight ) and mep percent predicted ( mep adjusted for age ) demonstrated a mean change from 91.7 percent at baseline to 89.5 percent at week 168 in mip percent predicted , and a mean change from 79.3 percent at baseline to 74.3 percent at week 168 in mep percent predicted . in addition , there was a mean increase in fvc , a measure of lung volume , of 11.6 percent . fvc percent predicted ( fvc adjusted for age and height ) was maintained above a mean of 90 percent at week 168 , with 101.3 percent at baseline and 91.9 percent at week 168. through 168 weeks , -55- eteplirsen was well tolerated and there were no reported clinically significant treatment-related adverse events and no treatment-related serious adverse events . in addition , there were no treatment-related hospitalizations or discontinuations . summary and timeline of marburg product candidate data disclosures non-human primates infected with marburg virus and treated with our precursor product candidate , avi-6003 , achieved 100 % survival and primates infected with ebola virus and treated with avi-6002 achieved 80 % survival , in each case compared to universal lethality in both control groups . in addition to survival , primates treated with avi-6002 and avi-6003 have demonstrated decreases in levels of viremia , in harmful inflammatory indicators and in virus induced liver damage . additional data have also demonstrated that the surviving animals were resistant to viral infection after subsequent injection with the virus . during the 2012 fiscal year , we completed phase i single ascending-dose studies in healthy adult volunteers with its drug candidates for the treatment of ebola virus and marburg virus demonstrating positive safety data for each therapeutic candidate . in february 2012 , we announced positive safety results from all six cohorts of our phase i single ascending dose trials of avi-6002 and avi-6003 . for each group , safety , clinical laboratory and renal biomarker results through five days after treatment were reviewed by an independent data and safety monitoring board ( dsmb ) , which issued recommendations for both studies to progress as planned to multiple ascending dose studies after no safety concerns were identified . the phase i single ascending dose trials were designed to characterize the safety , tolerability and pharmacokinetics of each therapeutic candidate in healthy adult volunteers . in the two studies , a total of 60 healthy human subjects ( five per group ) were enrolled into six sequential dose groups ( 0.01 , 0.1 , 1.0 , 3.0 , 6.0 or 9.0 mg/kg ) . within each group , four subjects received the indicated dose of the therapeutic and one subject received placebo . final , unblinded safety and pharmacokinetic results for all subjects were completed in 2012. in july 2012 , we announced that avi-7288 , one of the two components that make up avi-6003 , demonstrated up to 100 % survival in a non-human primate study exploring the drug 's effect when the initiation of treatment is delayed to various time points post-infection . this study showed a high degree of survival between 83 % and 100 % in each of four post-exposure cohorts that received daily treatments with avi-7288 beginning 1- , 24- , 48- , or 96-hours after infection , compared to 0 % survival in the placebo-treated control group . in march 2013 , we announced positive results from a non-human primate study of avi-7288 . the data showed that intramuscular administration of avi-7288 resulted in survival rates up to 100 percent in treated subjects , similar to efficacy observed in previous studies that evaluated the drug when administered by intravenous injection . we initiated a phase i multiple ascending dose study in may 2013 , designed to characterize the safety , tolerability and pharmacokinetics of multiple doses of avi-7288 in healthy adult volunteers . the randomized , double-blind and placebo-controlled study has been overseen by an independent dsmb , which reviewed the safety and clinical laboratory data after each dose cohort prior to enrolling the next higher dose cohort . the final cohort completed dosing in the first quarter of

